Composition for reducing body fat containing gallocatechin gallate and isoquercitrin

The combination of gallocatechin gallate and isoquercitrin addresses adipogenesis and fat accumulation issues by promoting lipolysis and increasing mitochondrial activity, offering a solution for obesity and metabolic disease management.

JP2024170291APending Publication Date: 2024-12-06AMOREPACIFIC CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024067003
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-04-17
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current technologies are inadequate in effectively inhibiting adipogenesis, fat accumulation, and promoting lipolysis for obesity and metabolic disease management.

Method used

A composition comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) is used to inhibit adipogenesis, suppress fat accumulation, and promote lipolysis, with a weight ratio ranging from 1:1 to 1:9, applicable in pharmaceutical and food compositions.

Benefits of technology

The composition exhibits excellent lipid metabolism control, increases mitochondria in adipocytes, promotes brown fat production, and enhances energy consumption, effectively reducing body fat and improving metabolic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024170291000001_ABST
    Figure 2024170291000001_ABST
Patent Text Reader

Abstract

To provide a composition for inhibiting lipogenesis; inhibiting fat accumulation; promoting fat breakdown; reducing body fat; and / or preventing, improving or treating obesity or metabolic diseases, containing Gallocatechin Gallate (GCG) and Isoquercitrin (IQC) as active ingredients.SOLUTION: In one aspect, a composition of the present invention has excellent lipid metabolism control effects, can increase mitochondria in adipocytes, and promote the production of brown fat. Therefore, in one aspect, the present invention can provide a pharmaceutical composition for preventing or treating obesity or metabolic diseases, and a food composition for preventing or treating obesity or metabolic diseases, or reducing body fat.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Disclosed herein is a composition for inhibiting adipogenesis, inhibiting fat accumulation, or promoting lipolysis. [Background technology]

[0002] Obesity is a condition caused by excessive body fat and metabolic abnormalities, and the number of obese patients has been steadily increasing over the past 20 years. Obesity is considered to be a major risk factor for various adult diseases such as hypertension, diabetes, and cardiovascular disease, as well as cancer. Therefore, anti-obesity treatment is important not only for weight loss but also for improving various obesity-related diseases such as hyperglycemia, dyslipidemia, and atherosclerotic heart disease. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Korean Patent Application Publication No. 2022-0145604 [Patent Document 2] Korean Patent Application Publication No. 2022-0071741 Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide a composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases.

[0005] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or metabolic diseases.

[0006] Another object of the present invention is to provide a food composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing or ameliorating obesity or metabolic diseases. [Means for solving the problem]

[0007] To achieve the above object, in one aspect, the present invention provides a composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases, comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) as active ingredients.

[0008] In another aspect, the present invention provides a pharmaceutical composition for preventing or treating obesity or metabolic diseases, comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) as active ingredients.

[0009] In another aspect, the present invention provides a food composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing or ameliorating obesity or metabolic diseases, which comprises gallocatechin gallate (GCG) and isoquercitrin (IQC) as active ingredients. [Effects of the Invention]

[0010] In one embodiment, the composition of the present invention has an excellent lipid metabolism controlling effect, and therefore exerts a significant effect of inhibiting adipogenesis, inhibiting fat accumulation, or promoting lipolysis.

[0011] In another embodiment, the composition of the present invention can increase mitochondria in adipocytes and effectively promote the production of brown fat. [Brief explanation of the drawings]

[0012] [Figure 1]FIG. 1 is a comparative diagram of changes in the expression of lipogenic genes in adipocytes at various composition ratios of a mixture (APGQ) of gallocatechin gallate (GCG) and isoquercitrin (IQC). [Figure 2] FIG. 1 is a graph comparing the increase in the expression of fatty acid oxidation-related genes at various composition ratios of APGQ. [Figure 3A] FIG. 1 is a comparison diagram of changes in the expression of fat metabolism-related genes (fat synthesis-inducing genes) at various composition ratios of APGQ. [Figure 3B] FIG. 1 is a comparison diagram of changes in the expression of fat metabolism-related genes (fatty acid oxidation-promoting genes) at various composition ratios of APGQ. [Figure 4] FIG. 1 shows an increase in the expression of mitochondrial structural genes in adipocytes by APGQ. [Figure 5] FIG. 1 shows an increase in the number of mitochondria in adipocytes by APGQ. [Figure 6] FIG. 1 shows an increase in UCP expression in adipocytes by APGQ. [Figure 7] 1 shows the increase in intracellular oxygen consumption by APGQ. The intracellular oxygen consumption was measured using an XF Analyzer (Seahorse). [Figure 8] FIG. 1 shows the inhibitory effect of APGQ on lipid accumulation in adipocytes.

[0013] In Figures 1 to 8, experimental groups showing statistically significant differences (P<0.01) are indicated by different symbols. DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention will be described in detail below.

[0015] In one aspect, the present invention relates to a composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases, comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 1:1 to 1:9.

[0016] In an exemplary embodiment, the gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 or more, 1:1.1 or more, 1:1.2 or more, 1:1.3 or more, 1:1.4 or more, 1:1.5 or more, 1:1.6 or more, 1:1.7 or more, 1:1.8 or more, 1:1.9 or more, 1:2.0 or more, 1:2.1 or more, 1:2.2 or more, 1:2.3 or more, 1:2.4 or more, or 1:2.5 or more, or in a weight ratio of 1:9 or less, 1:8 or less, 1:7 or less, 1:6 or less, 1:5 or less, 1:4 or less, 1:3.5 or less, 1:3.4 or less, 1:3.3 or less, 1:3.2 or less, 1:3.1 or less, 1:3 or less, 1:2.9 or less, 1:2.8 or less, 1:2.7 or less, or 1:2.6 or less. When gallocatechin gallate and isoquercitrin are contained in the above weight ratio, they can be effective in inhibiting fat production, inhibiting fat accumulation, or promoting fat decomposition. For example, gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 to 1:9 or 1:1.5 to 1:4, but the weight ratio is not limited thereto.

[0017] The term "application" as used herein means providing the composition to a subject by any suitable method, including administration, spreading, absorption, ingestion, etc. In this context, the subject refers to any animal to which the composition can be applied, such as a human, monkey, dog, goat, pig, or rat.

[0018] In one exemplary embodiment, the composition may be applied to a subject in need of reducing the expression of at least one gene selected from the group consisting of SREBP1c, ACC, and FAS.

[0019] In one exemplary embodiment, the composition may be applied to a subject in need of increasing the expression of at least one gene selected from the group consisting of ACO, CPT, PPARα, tfam, NDUFA9, COX4, ATP5a, UCP1, and UCP2.

[0020] In one exemplary embodiment, the composition may be applied to a subject in need of increasing mitochondria in adipocytes.

[0021] In one exemplary embodiment, the composition may be applied to a subject in need of promoting brown fat production.

[0022] In an exemplary embodiment, the daily dosage of the active ingredient of the composition may be 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, 9 mg / kg or more, 10 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 60 mg / kg or more, 70 mg / kg or more, 80 mg / kg or more, 90 mg / kg or more, 100 mg / kg or more, 1 g / kg or more, 2 g / kg or more, 3 g / kg or more, 4 g / kg or more, 5 g / kg or more, or 6 g / kg or more, or 60 g / kg or less, 59 g / kg or less, 58 g / kg or less, 57 g / kg or less, 56 g / kg or less, 55 g / kg or less, 54 g / kg or less, 53 g / kg or less, 52 g / kg or less, or 51 g / kg or less. The above-mentioned dosages are effective in inhibiting lipogenesis, inhibiting fat accumulation, or promoting lipolysis, while dosages lower than the above-mentioned dosages result in minimal effects in inhibiting lipogenesis, inhibiting fat accumulation, or promoting lipolysis, while dosages higher than the above-mentioned dosages may result in problems such as toxicity. The dosage may be administered once a day or in divided doses. For example, the dosage may be administered 2 to 24 times a day, 1 to 2 times every 3 days, 1 to 6 times a week, 1 to 10 times a week, 1 to 15 times a week, 1 to 3 times a week, or 1 to 12 times a year, but is not limited thereto.

[0023] In another aspect, the present invention relates to a method for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases, by applying effective amounts of gallocatechin gallate (GCG) and isoquercitrin (IQC) to a subject in a weight ratio of 1:1 to 1:9.

[0024] In another aspect, the present invention relates to the use of gallocatechin gallate (GCG) and isoquercitrin (IQC) for producing a composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases, and the composition may contain gallocatechin gallate and isoquercitrin in a weight ratio of 1:1 to 1:9.

[0025] In another aspect, the present invention relates to the use of gallocatechin gallate (GCG) and isoquercitrin (IQC) for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing, ameliorating, or treating obesity or metabolic diseases, wherein the weight ratio of gallocatechin gallate to isoquercitrin may be 1:1 to 1:9.

[0026] In another aspect, the present invention relates to non-therapeutic or therapeutic uses of gallocatechin gallate (GCLG) and isoquercitrin (IQC).

[0027] In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating obesity or metabolic diseases, which comprises gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 1:1 to 1:9.

[0028] The term "obesity" as used herein refers to a condition in which the body has excess adipose tissue. Men are said to be obese when their body fat exceeds 25% of their body weight, and women when it exceeds 30% of their body weight. Obesity occurs when the calories consumed through food exceed the calories burned through physical activity. Obesity not only makes people look fat, but can also cause shortness of breath, joint pain, diabetes, high blood pressure, and other symptoms.

[0029] The term "prevention" as used herein refers to any action of suppressing or delaying obesity or metabolic disorders by administering the pharmaceutical composition, and the term "treatment" refers to any action of improving or beneficially altering the symptoms of an individual suspected of or suffering from obesity or metabolic disorders by administering the pharmaceutical composition.

[0030] In one exemplary embodiment, the metabolic disease is a metabolic disease caused by obesity, and may include at least one selected from the group consisting of diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, and fatty liver.

[0031] In an exemplary embodiment, the gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 or more, 1:1.1 or more, 1:1.2 or more, 1:1.3 or more, 1:1.4 or more, 1:1.5 or more, 1:1.6 or more, 1:1.7 or more, 1:1.8 or more, 1:1.9 or more, 1:2.0 or more, 1:2.1 or more, 1:2.2 or more, 1:2.3 or more, 1:2.4 or more, or 1:2.5 or more, or in a weight ratio of 1:9 or less, 1:8 or less, 1:7 or less, 1:6 or less, 1:5 or less, 1:4 or less, 1:3.5 or less, 1:3.4 or less, 1:3.3 or less, 1:3.2 or less, 1:3.1 or less, 1:3 or less, 1:2.9 or less, 1:2.8 or less, 1:2.7 or less, or 1:2.6 or less. When gallocatechin gallate and isoquercitrin are contained in the above weight ratio, the preventive or therapeutic effect for obesity or metabolic diseases can be effectively achieved. For example, the gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 to 1:9 or 1:1.5 to 1:4, but the weight ratio is not limited thereto.

[0032] In one exemplary embodiment, the pharmaceutical composition may be characterized by being applied to a subject in need of reducing the expression of at least one gene selected from the group consisting of SREBP1c, ACC, and FAS.

[0033] In one exemplary embodiment, the pharmaceutical composition may be applied to a subject in need of increasing the expression of at least one gene selected from the group consisting of ACO, CPT, PPARα, tfam, NDUFA9, COX4, ATP5a, UCP1, and UCP2.

[0034] In one exemplary embodiment, the pharmaceutical composition may be applied to a subject in need of increasing mitochondria in adipocytes.

[0035] In one exemplary embodiment, the pharmaceutical composition may be applied to a subject in need of promoting the production of brown fat.

[0036] In an exemplary embodiment, the daily dosage of the active ingredient of the pharmaceutical composition may be 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, 9 mg / kg or more, 10 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 60 mg / kg or more, 70 mg / kg or more, 80 mg / kg or more, 90 mg / kg or more, 100 mg / kg or more, 1 g / kg or more, 2 g / kg or more, 3 g / kg or more, 4 g / kg or more, 5 g / kg or more, or 6 g / kg or more, or 60 g / kg or less, 59 g / kg or less, 58 g / kg or less, 57 g / kg or less, 56 g / kg or less, 55 g / kg or less, 54 g / kg or less, 53 g / kg or less, 52 g / kg or less, or 51 g / kg or less. The above-mentioned dosages provide excellent preventive or therapeutic effects for obesity or metabolic diseases, whereas lower dosages result in minimal preventive or therapeutic effects for obesity or metabolic diseases, and higher dosages may result in problems such as toxicity. The dosage may be administered once a day or in divided doses. For example, the dosage may be administered 2 to 24 times a day, 1 to 2 times every 3 days, 1 to 6 times a week, 1 to 10 times every 2 weeks, 1 to 15 times a week, 1 to 3 times a week, or 1 to 12 times a year, but is not limited thereto.

[0037] In another aspect, the present invention relates to the use of gallocatechin gallate (GCG) and isoquercitrin (IQC) for producing a pharmaceutical composition for the prevention or treatment of obesity or metabolic diseases, and the pharmaceutical composition may contain the gallocatechin gallate and isoquercitrin in a weight ratio of 1:1 to 1:9.

[0038] In one exemplary embodiment, the pharmaceutical composition may be provided in any dosage form suitable for topical application. For example, it may be administered orally, transdermally, intravenously, intramuscularly, or subcutaneously. For example, the pharmaceutical composition may be, but is not limited to, an injection, a solution for topical application, a suspension, an emulsion, a gel, a patch, or a spray. The dosage form may be easily prepared according to a conventional method in the art, and may contain surfactants, excipients, hydrating agents, emulsifiers, suspending agents, salts or buffers for adjusting osmotic pressure, coloring agents, spices, stabilizers, preservatives, or other commonly used auxiliary substances, as appropriate.

[0039] In an exemplary embodiment, the active ingredient of the pharmaceutical composition will depend on the subject's age, sex, weight, condition and its severity, the route of administration, or the prescriber's discretion. Determination of the appropriate dosage based on such factors is within the skill of one in the art.

[0040] In another aspect, the present invention relates to a food composition comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 1:1 to 1:9, for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing or ameliorating obesity or metabolic diseases.

[0041] The term "amelioration" as used herein means any action in which obesity or metabolic disorders are ameliorated or beneficially altered by application of the composition.

[0042] In one exemplary embodiment, the metabolic disease is a metabolic disease caused by obesity, and may include at least one selected from the group consisting of diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, and fatty liver.

[0043] In an exemplary embodiment, the gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 or more, 1:1.1 or more, 1:1.2 or more, 1:1.3 or more, 1:1.4 or more, 1:1.5 or more, 1:1.6 or more, 1:1.7 or more, 1:1.8 or more, 1:1.9 or more, 1:2.0 or more, 1:2.1 or more, 1:2.2 or more, 1:2.3 or more, 1:2.4 or more, or 1:2.5 or more, or in a weight ratio of 1:9 or less, 1:8 or less, 1:7 or less, 1:6 or less, 1:5 or less, 1:4 or less, 1:3.5 or less, 1:3.4 or less, 1:3.3 or less, 1:3.2 or less, 1:3.1 or less, 1:3 or less, 1:2.9 or less, 1:2.8 or less, 1:2.7 or less, or 1:2.6 or less. When gallocatechin gallate and isoquercitrin are contained in the above weight ratio, the effects of preventing or ameliorating obesity or metabolic diseases, or reducing body fat can be achieved. For example, gallocatechin gallate and isoquercitrin may be contained in a weight ratio of 1:1 to 1:9 or 1:1.5 to 1:4, but the weight ratio is not limited thereto.

[0044] In one exemplary embodiment, the food composition may be characterized in that it is applied to a subject in need of reducing the expression of at least one gene selected from the group consisting of SREBP1c, ACC, and FAS.

[0045] In one exemplary embodiment, the food composition may be applied to a subject in need of increasing the expression of at least one gene selected from the group consisting of ACO, CPT, PPARα, tfam, NDUFA9, COX4, ATP5a, UCP1, and UCP2.

[0046] In one exemplary embodiment, the food composition may be applied to a subject in need of increasing mitochondria in adipocytes.

[0047] In one exemplary embodiment, the food composition may be applied to a subject in need of promoting the production of brown fat.

[0048] In an exemplary embodiment, the daily dosage of the food composition may be 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, 9 mg / kg or more, 10 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 60 mg / kg or more, 70 mg / kg or more, 80 mg / kg or more, 90 mg / kg or more, 100 mg / kg or more, 1 g / kg or more, 2 g / kg or more, 3 g / kg or more, 4 g / kg or more, 5 g / kg or more, or 6 g / kg or more, or 60 g / kg or less, 59 g / kg or less, 58 g / kg or less, 57 g / kg or less, 56 g / kg or less, 55 g / kg or less, 54 g / kg or less, 53 g / kg or less, 52 g / kg or less, or 51 g / kg or less. The above-mentioned dosages are effective in preventing or ameliorating obesity or metabolic diseases, or reducing body fat. Less than the above dosages result in only a slight effect in preventing or ameliorating obesity or metabolic diseases, or reducing body fat. More than the above dosages may result in problems such as toxicity. The dosage may be divided into one or several times per day. For example, the dosage may be, but is not limited to, two to 24 times per day, one to two times per three days, one to six times per week, one to ten times per two weeks, one to 15 times per three weeks, one to three times per four weeks, or one to twelve times per year.

[0049] In another aspect, the present invention relates to the use of gallocatechin gallate (GCG) and isoquercitrin (IQC) for producing a food composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, reducing body fat, and / or preventing or ameliorating obesity or metabolic diseases, and the food composition may contain gallocatechin gallate and isoquercitrin in a weight ratio of 1:1 to 1:9.

[0050] In an exemplary embodiment, when the composition is used as an additive for a health functional food, it may be added as it is or in combination with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately determined depending on the intended use, such as prevention, health, or treatment. The dosage form of the health functional food may be in the form of powder, granules, pills, tablets, capsules, or any of general food or beverage forms.

[0051] In an exemplary embodiment, the type of the health functional food is not particularly limited, and examples of foods to which the composition can be added include meat, confectionery, noodles, gum, dairy products such as ice cream, various soups, soft drinks, tea, energy drinks, alcoholic beverages, and vitamin complexes, and may include all foods in the usual sense.

[0052] In one exemplary embodiment, the composition may be added in an amount of 15% by weight or less, preferably 10% by weight or less, based on 100 parts by weight of the raw materials when producing the health functional food or beverage. However, for long-term intake for health and hygiene purposes or health regulation purposes, the amount may be less than the above range.

[0053] In one exemplary embodiment, the beverage in the health functional food may contain various flavorings, natural carbohydrates, and other additional ingredients, similar to ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; or sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of sweeteners that can be used include natural sweeteners such as thaumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates per 100 mL of the beverage according to the present invention may be, but is not limited to, approximately 0.01 to 0.04 g, preferably approximately 0.02 to 0.03 g.

[0054] In an exemplary embodiment, the health functional food according to the present invention may further contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloids, thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonation agents used in carbonated beverages. The health functional food according to the present invention may also contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used alone or in combination. The proportion of these additives is not limited, but is typically selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food according to the present invention.

[0055] The following examples will explain the configuration and effects of the present invention in more detail. However, the following examples are provided to aid in understanding the present invention, and the scope and spirit of the present invention are not limited thereto.

[0056] <Example> [Example 1] Changes in lipid metabolism-related gene expression in adipocytes treated with gallocatechin gallate and isoquercitrin The main role of adipocytes is to store excess energy in the form of fat. When excess energy accumulates, the amount of fat stored in adipocytes increases, causing the adipocytes to enlarge and resulting in changes in body shape. Preventing the conversion and accumulation of excess nutrients into fat is the most fundamental solution to obesity.

[0057] The present inventors conducted the following experiment to determine the effect of a mixture of galcocatacin gallate (GCG) and isoquercitrin (IQC) (APGQ) on the expression of lipid metabolism regulating genes in adipocytes and the GCG:IQC ratio that can maximize this expression.

[0058] 3T3-L1 preadipocytes were purchased from ATCC and cultured in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich) containing 10% bovine calf serum (Gibco) and 1% penicillin / streptomycin (P / S; Sigma-Aldrich). 3T3-L1 cells were grown until the culture dish was 100% full, after which they were cultured in the same medium for an additional 2 days to induce clonal expansion. To differentiate preadipocytes into adipocytes, the cells were treated with DMEM containing dexamethasone (1 mM; Sigma Aldrich), insulin (10 mg / mL; Sigma Aldrich), and 3-isobutyl-1-methylxanthine (0.5 mM; Sigma Aldrich) + 10% fetal bovine serum (FBS; Gibco) + 1% P / S for 48 hours, followed by culturing in DMEM with 10% FBS + 10 mg / mL insulin + 1% P / S every 2 days for 10 days to induce complete adipocyte differentiation.

[0059] Differentiated adipocytes were treated with GCG and IQC at various ratios (10:0 to 0:10, with the GCG + IQC treatment concentration fixed at 100 mg / mL) for 24 hours, and then the expression of lipogenesis-related genes (Figure 1) and fatty acid oxidation-related genes (Figure 2) was measured. For the experiment, cells were washed twice with phosphate-buffered saline (PBS; Sigma-Aldrich). The PBS was then removed, and RNA was extracted using the TaKaRa MiniBEST Universal RNA Extraction Kit (Takara Bio). After RNA quantification using a Tecan Infinite M200 (Tecan), an equal amount (1 mg) of RNA was transferred to RevertAid 1 st cDNA was synthesized using a one-strand cDNA Synthesis Kit (Thermo Fisher Scientific). To observe the expression of the target gene, the coding sequence of the target gene was used as a template and the cDNA was analyzed using NCBI primer BLAST ( https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / ) service, and fabricated by Bioneer. Changes in the expression of fat metabolism-related genes were observed using a CFX96 thermocycler (Bio-Rad).

[0060] As a result, as shown in Figures 1 and 2, although there were differences depending on the composition ratio, it was confirmed that combined treatment with GCG and IQC had a synergistic effect on lipid metabolism control. Although there were slight differences depending on the lipid metabolism target gene, a significant gene expression regulation effect was observed at a GCG:IQC ratio of 4:6 to 2:8, with the most excellent effect being observed at 3:7.

[0061] Therefore, we further subdivided the GCG:IQC ratio range of 4:6 to 2:8 (1:1.5 to 1:4) and reconfirmed the expression patterns of fat synthesis and oxidation-related genes (Figures 3A and 3B). As a result, a GCG:IQC ratio range of 1:2 to 1:3 exhibited a superior effect on the regulation of fat metabolism-related gene expression, with the most effective effect observed in the GCG:IQC ratio range of 1:2.5 to 1:2.6. Therefore, subsequent experiments were performed with the GCG:IQC ratio of APGQ fixed at 1:2.5.

[0062] [Example 2] Activation of mitochondria and brown fat in adipocytes by treatment with gallocatechin gallate and isoquercitrin As confirmed in Example 1, APGQ, a mixture of GCG and IQC in a certain ratio, regulated the expression of genes involved in the synthesis and degradation of fatty acids. Fatty acid oxidation breaks down neutral fats to generate free fatty acids, which then migrate into mitochondria and undergo hydrolysis, producing acetyl-CoA. The generated acetyl-CoA then passes through the Krebs cycle and electron transport chain to produce ATP. Mitochondria are abundant in muscle and liver tissue cells, which have active energy metabolism, and it is known that adipocytes contain fewer mitochondria than muscle and liver cells. For smooth fat oxidation in adipocytes, the amount of mitochondria within the adipocytes must also be increased.

[0063] To investigate whether APGQ can induce mitochondrial biogenesis in adipocytes, differentiated adipocytes were treated with APGQ at various concentrations (10-100 mg / mL) for 24 hours, and RNA was extracted and cDNA synthesized using the same method as in Example 1. The expression of mitochondria-related genes was then monitored by Q-PCR (Figure 4). Furthermore, to investigate whether the amount of mitochondria in adipocytes actually increased, differentiated adipocytes were treated with the same concentrations of APGQ for 48 hours and then washed with PBS. Then, Mitotracker was used. TM The mitochondria were stained with Green FM (Invitrogen; 20 nM) for 30 minutes, and then the fluorescence was measured and quantified using a TECAN Infinite M200 multiplate reader (ex 490 nm, em 512 nm) (Figure 5).

[0064] As shown in Figures 4 and 5, treatment of adipocytes with APGQ resulted in a concentration-dependent increase in the number of mitochondria, as well as in the expression of mitochondrial biogenesis (tfam) and electron transport chain component genes (NDUFA9, COX4, ATP5a). In other words, APGQ suppresses fatty acid synthesis and promotes fatty acid oxidation, thereby activating mitochondria and increasing energy consumption in adipocytes to ensure smooth fat metabolism.

[0065] The difference in hydrogen ion concentration between the inside and outside of the mitochondrial inner membrane is crucial for ATP synthesis via the mitochondrial electron transport chain. In some cases, this difference in hydrogen ion concentration can be used to maintain the temperature required for cell survival (thermogenesis) by converting it into heat rather than ATP synthesis. Uncoupling proteins (UCPs) are known to play this role. The specialized tissue for this function is brown fat, which contains many mitochondria and is commonly found in hibernating animals. Interestingly, recent research has shown that humans also have brown fat, and that its amount is high in young children and gradually decreases with maturation as the thermoregulatory center develops. The higher the amount of uncoupling proteins, the more heat is converted into ATP without producing ATP. From a cellular perspective, increased UCPs require the breakdown of more nutrients to produce the ATP required to maintain cellular function. Therefore, it has become clear that the distribution and activity of brown fat are closely related to obesity, and brown fat activation has become a new target for obesity treatment. When white fat cells are treated with a b-adrenergic receptor agonist, UCP1 increases along with mitochondria, resulting in a transformation similar to brown fat, which is called beige fat cells. Brown fat and beige fat share a commonality in the presence of a large number of mitochondria in adipocytes. Therefore, to investigate whether APGQ can induce brown fat formation along with an increase in mitochondria in adipocytes, we further examined the expression of UCP (Figure 6).

[0066] As a result, the expression of UCP1, which is only present in brown fat, was increased along with UCP2, which is involved in oxidative stress. This indicates that APGQ induces the browning of white fat and promotes energy metabolism. In fact, APGQ-treated cells showed a significant increase in cellular oxygen consumption (i.e., mitochondrial oxygen respiration) (Figure 7). This result supports the idea that APGQ treatment maximizes intracellular energy metabolism.

[0067] [Example 3] Inhibitory effect of gallocatechin gallate and isoquercitrin on lipid accumulation in adipocytes Since Examples 1 and 2 confirmed that APGQ inhibits fatty acid synthesis, induces adipose browning in adipocytes, and promotes fat loss, the following experiment was conducted to confirm whether APGQ can actually reduce the amount of fat accumulated in adipocytes through this series of mechanisms.

[0068] Differentiated adipocytes were treated with various concentrations of APGQ (10, 20, 50, and 100 mg / mL) for 72 hours. The cells were then washed twice with PBS and fixed with 10% formaldehyde (Sigma-Aldrich) solution for 5 minutes. The accumulated triglycerides were then stained with Nile Red (Sigma-Aldrich; 300 nM). The amount of accumulated lipids was quantified using a Tecan Infinite M200 Multiplate Reader (ex 495 nm, emi 585 nm) (Figure 8).

[0069] As a result, it was confirmed that treatment with APGQ reduces the amount of triglycerides accumulated in 3T3-L1 adipocytes through various lipid metabolism regulating effects.

Claims

1. A composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting lipolysis, and / or preventing, ameliorating, or treating obesity or metabolic diseases, comprising gallocatechin gallate (GCG) and isoquercitrin (IQC) in a weight ratio of 1:1 to 1:

9.

2. The composition according to claim 1 , wherein the composition is a pharmaceutical composition for the prevention or treatment of obesity or a metabolic disease.

3. The composition according to claim 1, which is a food composition for inhibiting adipogenesis, inhibiting fat accumulation, promoting fat decomposition, reducing body fat, and / or preventing or ameliorating obesity or metabolic diseases.

4. The composition according to any one of claims 1 to 3, characterized in that the composition is applied to a subject in need of reducing the expression of at least one gene selected from the group consisting of SREBP1c, ACC, and FAS.

5. The composition according to any one of claims 1 to 3, characterized in that the composition is applied to a subject in need of increasing expression of at least one gene selected from the group consisting of ACO, CPT, PPARα, tfam, NDUFA9, COX4, ATP5a, UCP1, and UCP2.

6. The composition according to any one of claims 1 to 3, wherein the composition is applied to a subject in need of increasing mitochondria in adipocytes.

7. The composition according to any one of claims 1 to 3, characterized in that the composition is applied to a subject in need of promoting the production of brown fat.

8. The composition according to any one of claims 1 to 3, wherein the daily dosage of the active ingredient of the composition is 5 mg / kg or more.

9. The composition according to any one of claims 1 to 3, wherein the daily dosage of the active ingredient of the composition is 10 mg / kg or more.

10. The composition according to any one of claims 1 to 3, comprising the gallocatechin gallate and isoquercitrin in a weight ratio of 1:1.5 to 1:

4.

11. The composition according to any one of claims 1 to 3, comprising the gallocatechin gallate and isoquercitrin in a weight ratio of 1:2.2 to 1:2.8.

Citation Information

Patent Citations

  • KR2022-0071741

  • KR2022-0145604